At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 44 enrolled
Drug / intervention
vismodegib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Biomarker and Phase II Study of GDC-0449 in Patients With Recurrent Glioblastoma Multiforme
In Brief
A Phase 2 clinical trial evaluating vismodegib, therapeutic conventional surgery, and 2 other interventions for Adult Giant Cell Glioblastoma and 3 related conditions. Completed, enrolled 44 participants across 9 sites.
Detailed Summary
This randomized phase II trial is studying how well GDC-0449 works in treating patients with recurrent glioblastoma multiforme that can be removed by surgery. GDC-0449 may be effective in treating patients with glioblastoma multiforme.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2009
Enrollment StartFeb 2010
Primary CompletionMay 2012
Study CompletionJun 2012
TodayJul 2026
First PostedSep 21, 2009
Enrollment StartFeb 1, 2010
Primary CompletionMay 1, 2012
Study CompletionJun 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 16.8 years ago
Interventions
vismodegibdrug
Given orally
therapeutic conventional surgeryprocedure
undergo surgery
laboratory biomarker analysisother
correlative studies
pharmacological studyother
correlative studies